62nd ASH Annual Meeting and Exposition: 704. Immunotherapies: Poster I

Oral and Poster Abstracts
Poster

Adult, ALL, antibodies, Biological, Coronaviruses, CRS, Leukemia, SARS-CoV-2/COVID-19, Diseases, iPSCs, neurotoxicity, CAR-Ts, Therapies, Adverse Events, Non-Hodgkin Lymphoma, Pediatric, B-Cell Lymphoma, Biological Processes, DLBCL, Technology and Procedures, Cell Lineage, immunotherapy, gene editing, Lymphoid Malignancies, Study Population, Clinically relevant, NK cells, immune mechanism, transplantation, stem cells

1440

Clinical Characterization and Risk Factors Associated with Cytokine Release Syndrome Induced By COVID-19 and Chimeric Antigen Receptor T-Cell Therapy

Ruimin Hong¹^*, Houli Zhao, MD²^*, Yiyun Wang³^*, Yu Chen⁴^*, Hongliu Cai⁵^*, Yongxian Hu, MD³^*, Guoqing Wei, MD²^* and He Huang, MD, PhD^2,3,6,7,8,9

¹Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China
²Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
³Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
⁴Department of Clinical Laboratory, Department of Clinical Laboratory, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Zhejiang, China
⁵Department of Surgical Intensive Care Unit (SICU), Department of Surgical Intensive Care Unit (SICU), The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China., Zhejiang, China
⁶the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
⁷Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
⁸Institute of Hematology, Zhejiang University, Hangzhou, China
⁹Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

1441

Safety and Antitumor Effects of CD19-Specific Autologous Chimeric Antigen Receptor-Modified T (CAR-T) Cells Expressing the Inducible Caspase 9 Safety Switch (iC9-CAR19 T Cells) in Adult Acute Lymphoblastic Leukemia (ALL)

Matthew C Foster, MD¹, Philip A. Roehrs, MD², George E Hucks, MD³^*, Natalie S Grover, MD⁴, Paul M. Armistead, MD, PhD⁴, Katarzyna Jamieson, MD⁴^*, Faith Brianne Buchanan, PA⁵^*, J. Kaitlin C Morrison, PhD⁴^*, Spencer Laing, BA⁴^*, Catherine Joyce Arago Cheng, BS⁴^*, Jonathan S. Serody, MD⁴, Gianpietro Dotti, MD⁴^* and Barbara Savoldo, MD, PhD⁴^*

¹Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, Chapel Hill, NC
²Carolinas Medical Center, Charlotte, NC
³Division of Pediatric Hematology/Oncology and Bone Marrow Transplant, University of North Carolina, Chapel Hill, NC
⁴Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
⁵Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC

1442

High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics

Jordan Gauthier, MD, MSc^1,2, Cassie Chou, MD, PhD^2,3, Alexandre V. Hirayama, MD², Salvatore Fiorenza, MBBS, PhD²^*, Alyssa Sheih, PhD²^*, Barbara S. Pender, MSc²^*, Tinh-Doan Phi, BSc²^*, Rachel Steinmetz, BSc²^*, Abby Jamieson, BSc²^*, Delaney R Kirchmeier, BSc²^*, Henna N Di, BSc²^*, Stanley R. Riddell, MD^1,2^*, David G. Maloney, MD, PhD^1,2 and Cameron J. Turtle, MBBS, PhD^1,2

¹Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA
²Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
³Pediatric Hematology/Oncology, University of Washington/Seattle Children's Hospital, Seattle, WA

1443

Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Mazyar Shadman, MD¹, Cecilia Yeung, MD^2,3^*, Mary W Redman, PhD⁴^*, Sang Yun Lee, Ph.D.⁵^*, Dong Hoon Lee, B.S.⁵^*, Ajeetha Ramachandran, PhD⁶^*, Susan Ra, BS⁴^*, Edmond A Marzbani, MD⁷^*, Solomon A. Graf, MD⁸, Edus H. Warren, MD, PhD^4,7, Ajay K. Gopal, MD⁹, Aude G. Chapuis, MD⁴, Merav Bar^4,7, Damian J. Green, MD^4,10, Jordan Gauthier, MD, MSc², Ryan D. Cassaday, MD¹¹, Hans-Peter Kiem, MD, PhD^4,7^*, Cameron J. Turtle, MBBS, PhD^12,13, David G. Maloney, MD, PhD^4,13 and Brian G. Till, MD^2,14

¹Uw/Fred Hutchinson Cancer Research Center, Seattle, WA
²Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
³Department of Pathology, University of Washington, Seattle, WA
⁴Fred Hutchinson Cancer Research Center, Seattle, WA
⁵Fred Hutchinson Cancer Research Center, Seattle
⁶Mustang Bio, Worcester, MA
⁷University of Washington, Seattle, WA
⁸Department of Medicine, Division of Oncology, University of Washington, Seattle, WA
⁹University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA
¹⁰Department of Medicine, University of Washington, Seattle, WA
¹¹UW/FHCRC, Seattle, WA
¹²Clinical Research Division, Fred Hutchinson Cancer Research Ctr., Seattle, WA
¹³Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA
¹⁴Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA

1444

Allogeneic Hematopoietic Cell Transplantation Is Critical to Maintain Remissions after CD19-CAR T-Cell Therapy for Pediatric ALL: A Single Center Experience

Aimee C Talleur, MD¹, Renee M. Madden, MS, MD¹^*, Amr Qudeimat, MD¹^*, Ewelina Mamcarz, MD¹, Akshay Sharma, MBBS¹, Ashok Srinivasan, MD¹^*, Ali Y Suliman, MD¹^*, Mireya Paulina Velasquez, MD¹, Timothy Lockey, PhD²^*, Alisha Gaboriault¹^*, Seth E. Karol, MD³, Hiroto Inaba, MD, PhD³, Ying Li, MD, PhD¹^*, Pam Young¹^*, Guolian Kang, PhD⁴^*, Cheng Cheng, PhD⁴^*, Wenting Zheng, PhD⁵^*, Sheng Zhou, PhD⁶, Salem M. Akel, PhD⁷^*, Terrence L Geiger, MD, PhD⁵^*, Michael M Meagher, PhD²^*, Ching-Hon Pui, MD⁸, Brandon M Triplett, MD¹^* and Stephen Gottschalk, MD¹

¹Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN
²Department of Therapeutics Production and Quality, St. Jude Children's Research Hospital, Memphis, TN
³Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN
⁴Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN
⁵Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
⁶Experimental Cellular Therapeutics Laboratory, St. Jude Children's Research Hospital, Memphis, TN
⁷Human Applications Lab, St. Jude Children's Research Hospital, Memphis, TN
⁸Department of Oncology, Member, St Jude Faculty, Chair, Oncology Department, Coleader, Hematological Malignancies Program, Director, China Region, St Jude Global, American Cancer Society Professor, Fahad Nassar Al-Rashid Chair of Leukemia Research, St Jude Children’s Research H, Memphis, TN

1445

Significant Long-Term Benefits of CAR T-Cell Therapy Followed By a Second Allo-HSCT for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Who Relapsed after an Initial Transplant

Jianping Zhang¹^*, Junfang Yang^2,3^*, Xian Zhang, MD^2,3, Jingjing Li^2,3^*, Xingyu Cao¹^*, Yanli Zhao¹^*, Zhijie Wei¹^*, Deyan Liu¹^*, Min Xiong³^*, Yue Lu¹^*, Jiarui Zhou³^*, Ruijuan Sun¹^* and Peihua Lu, MD^2,3

¹Bone Marrow Transplant Department, Hebei Yanda Lu Daopei Hospital, Langfang, China
²Beijing Lu Daopei Institute of Hematology, Beijing, China
³Hebei Yanda Lu Daopei Hospital, Langfang, China

1446

Identification of Predictive Markers of Severe and Prolonged Neutropenia after CD19-Specific CAR T-Cell Treatment in Patients with Relapsed/Refractory B-Cell Malignancies

Kai Rejeski, MD¹^*, Carolina Berger²^*, Liv Jentzsch³^*, Semjon Willier, MD⁴^*, Viktoria Blumenberg, MD¹^*, Veit Buecklein, MD¹^*, Christoph Faul, MD³, Christian Schmidt, MD¹^*, Michael von Bergwelt, MD, PhD¹^*, Tobias Feuchtinger, MD⁴, Wolfgang Bethge, MD³^*, Francis A. Ayuk²^* and Marion Subklewe, MD¹

¹Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
²UKE Hamburg-Eppendorf, Hamburg, Germany
³University Hospital Tübingen, Tübingen, Germany
⁴Dr. Von Hauner University Children's Hospital, LMU, Munich, Germany

1447

Unbiased Metabolomic Screening Reveals Pre-Existing Plasma Signatures in Large B-Cell Lymphoma Patients Treated with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cells: Association with Cytokine Release Syndrome (CRS) and Neurotoxicity (ICANS)

Akansha Jalota, PhD, MSc, BSc¹^*, Courtney E. Hershberger, PhD², Manishkumar S. Patel, PhD, MS, BPharm¹, Agrima Mian, MBBS, MD³^*, Daniel M. Rotroff, PhD²^*, Brian T. Hill, MD³ and Neetu Gupta, PhD, MSc, BSc¹

¹Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH
²Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
³Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

1448

Clinical Impact of Bridging Therapy Prior to Commercial Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Lymphomas

Brandon S. Imber, MD, MA¹, Miguel-Angel Perales, MD², Jessica Flynn, BS³^*, Josel D Ruiz, MPH²^*, Sean Devlin, PhD⁴^*, Ana Alarcon Tomas, MD⁵^*, Carla Hajj, MD⁵^*, Connie Lee Batlevi, MD, PhD⁶, Parastoo B. Dahi, MD⁷, Richard J Lin, MD, PhD⁵, Jae H. Park, MD⁸, Michael Scordo, MD⁹, Gunjan L. Shah, MD MS², Sergio A. Giralt, MD¹⁰, Craig S. Sauter, MD¹¹, M. Lia Palomba, MD¹² and Joachim Yahalom, MD⁶

¹Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
²Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY
³Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
⁵Memorial Sloan Kettering Cancer Center, New York, NY
⁶Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁷Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, NY
⁸Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY
⁹Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center/New York, New York, NY
¹⁰Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY
¹¹Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY
¹²Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

1449

A Phase I Study of FT538, a First-of-Kind, Off-the-Shelf, Multiplexed Engineered, iPSC-Derived NK Cell Therapy As Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Daratumumab or Elotuzumab in Relapsed/Refractory Multiple Myeloma

Murali Janakiram, MD¹, Ravi Vij, MBBS², David S. Siegel, MD³, Ted Shih, PharmD⁴^*, Sara Weymer⁴^*, Bahram Valamehr, PhD⁴, Yu-Waye Chu, MD⁴ and Jeffrey S. Miller, MD¹

¹Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
²Division of Medical Oncology, Washington University in St Louis, St Louis, MO
³Hackensack Univ. Med. Ctr., Hackensack, NJ
⁴Fate Therapeutics, Inc., San Diego, CA

1450

Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma

Armin Ghobadi, MD^*, Michael P. Rettig, PhD, Amanda F Cashen, MD, Leah Gehrs^*, Stephanie Christ, MS^*, Neha Mehta-Shah, MD, Peter Westervelt, MD, PhD, Brad S. Kahl, MD, Nancy L. Bartlett, MD and John F. DiPersio, MD

Washington University School of Medicine, Saint Louis, MO

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

704.P1.39 704. Immunotherapies: Poster I